Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making

S. Gonzalez-McQuire, MA. Dimopoulos, K. Weisel, W. Bouwmeester, R. Hájek, M. Campioni, C. Bennison, W. Xu, K. Pantiri, M. Hensen, E. Terpos, S. Knop,

. 2019 ; 4 (1) : 2381468318814253. [pub] 20190117

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19013391

Background. We aimed to develop and validate a conceptual model of multiple myeloma (MM) that characterizes the attributes affecting disease progression and patient outcomes, and the relationships between them. Methods. Systematic and targeted literature reviews identified disease- and patient-specific attributes of MM that affect disease progression and outcomes. These attributes were validated by a Delphi panel of four international MM experts, and a physician-validated model was constructed. Real-world clinical data from the Czech Registry of Monoclonal Gammopathies (RMG) was used to confirm the relationships between attributes using pairwise correlations and multiple Cox regression analysis. Results. The Delphi panel reached consensus that most cytogenetic abnormalities influenced disease activity, which results in symptoms and complications and affects overall survival (OS). Comorbidities and complications also affect OS. The entire panel agreed that quality of life was influenced by comorbidities, age, complications, and symptoms. Consensus was not reached in some cases, in particular, the influence of del(17p) on complications. The relationships between attributes were confirmed using pairwise analysis of real-world data from the Czech RMG; most of the correlations identified were statistically significant and the strength of the correlations changed with successive relapses. Czech RMG data were also used to confirm significant predictors of OS included in the model, such as age, Eastern Cooperative Oncology Group performance status, and extramedullary disease. Conclusions. This validated conceptual model can be used for economic modeling and clinical decision making. It could also inform the development of disease-based models to explore the impact of disease progression and treatment on outcomes in patients with MM.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19013391
003      
CZ-PrNML
005      
20210208134921.0
007      
ta
008      
190405s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2381468318814253 $2 doi
035    __
$a (PubMed)30729167
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gonzalez-McQuire, Sebastian $u Amgen (Europe) GmbH, Rotkreuz Switzerland.
245    10
$a Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making / $c S. Gonzalez-McQuire, MA. Dimopoulos, K. Weisel, W. Bouwmeester, R. Hájek, M. Campioni, C. Bennison, W. Xu, K. Pantiri, M. Hensen, E. Terpos, S. Knop,
520    9_
$a Background. We aimed to develop and validate a conceptual model of multiple myeloma (MM) that characterizes the attributes affecting disease progression and patient outcomes, and the relationships between them. Methods. Systematic and targeted literature reviews identified disease- and patient-specific attributes of MM that affect disease progression and outcomes. These attributes were validated by a Delphi panel of four international MM experts, and a physician-validated model was constructed. Real-world clinical data from the Czech Registry of Monoclonal Gammopathies (RMG) was used to confirm the relationships between attributes using pairwise correlations and multiple Cox regression analysis. Results. The Delphi panel reached consensus that most cytogenetic abnormalities influenced disease activity, which results in symptoms and complications and affects overall survival (OS). Comorbidities and complications also affect OS. The entire panel agreed that quality of life was influenced by comorbidities, age, complications, and symptoms. Consensus was not reached in some cases, in particular, the influence of del(17p) on complications. The relationships between attributes were confirmed using pairwise analysis of real-world data from the Czech RMG; most of the correlations identified were statistically significant and the strength of the correlations changed with successive relapses. Czech RMG data were also used to confirm significant predictors of OS included in the model, such as age, Eastern Cooperative Oncology Group performance status, and extramedullary disease. Conclusions. This validated conceptual model can be used for economic modeling and clinical decision making. It could also inform the development of disease-based models to explore the impact of disease progression and treatment on outcomes in patients with MM.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dimopoulos, Meletios-Athanassios $u National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
700    1_
$a Weisel, Katja $u University Hospital of Tübingen, Tübingen, Germany.
700    1_
$a Bouwmeester, Walter $u Pharmerit International, Rotterdam, Netherlands.
700    1_
$a Hájek, Roman $u Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Campioni, Marco $u Amgen (Europe) GmbH, Rotkreuz Switzerland.
700    1_
$a Bennison, Craig $u Pharmerit Ltd, York, UK.
700    1_
$a Xu, Weiwei $u Pharmerit International, Rotterdam, Netherlands.
700    1_
$a Pantiri, Krystallia $u Pharmerit International, Rotterdam, Netherlands.
700    1_
$a Hensen, Marja $u Pharmerit International, Rotterdam, Netherlands.
700    1_
$a Terpos, Evangelos $u National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
700    1_
$a Knop, Stefan $u Würzburg University Medical Center, Würzburg, Germany.
773    0_
$w MED00198764 $t MDM policy & practice $x 2381-4683 $g Roč. 4, č. 1 (2019), s. 2381468318814253
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30729167 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20210208134920 $b ABA008
999    __
$a ind $b bmc $g 1392701 $s 1051696
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 4 $c 1 $d 2381468318814253 $e 20190117 $i 2381-4683 $m MDM policy & practice $n MDM Policy Pract $x MED00198764
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options